AIFF · May 15, 2026NASDAQAIFFCoverage Bootstrap

+10

WatchlistResearch report read

Interactive slide deck

AIFF diligence lens

AIFF: Firefly's brain-data platform still has to prove the cash can last

Firefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings, controls were ineffective and management disclosed substantial doubt about going concern.

ClaimFilingCashCustomerConviction

Slide mode Article mode

Firefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings, controls were ineffective and management disclosed substantial doubt about going concern.

References

Sources used in this report

SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-15 · Issuer identity, CIK, exchange and ticker cross-check.SEC APIAIFF SEC submissions APIRetrieved 2026-05-15 · Filing chronology, former names, fiscal year end and issuer metadata.SEC XBRL APIAIFF SEC companyfacts APIRetrieved 2026-05-15 · XBRL-derived financial cross-checks.Annual reportFY2025 Form 10-K2026-03-31 · Annual financials, business model, Evoke acquisition, database metrics, risk factors, controls, employees and liquidity.Quarterly reportQ1 2026 Form 10-Q2026-05-13 · Latest financials, cash, revenue mix, recent financings, controls and going-concern update.Quarterly reportQ3 2025 Form 10-Q2025-11-12 · Earlier current-period baseline and historical financing/product context.Current reportMay 2026 unit purchase agreement 8-K2026-05-12 · May unit financing, warrant terms, shareholder approval and registration-statement conditions.Current reportApril 2026 additional closing 8-K2026-04-22 · Additional private-placement closing, gross proceeds and lock-up changes.Current reportMarch 2026 units offering 8-K2026-03-12 · Initial private-placement terms, units, warrants and lock-up framework.Current reportFebruary 2026 ATM offering 8-K2026-02-04 · At-the-market offering agreement and potential sales capacity.Prospectus supplementFebruary 2026 ATM prospectus supplement2026-02-03 · ATM program details and use-of-proceeds disclosure.Company websiteFirefly investor relations homepageRetrieved 2026-05-15 · Company-controlled overview, platform positioning and latest filings links.FDA databaseFDA 510(k) Premarket Notification K171781Page updated 2026-05-11 · Independent regulator record for Evoke Neuroscience eVox System clearance lineage.